Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26457766 | 1.00 | TSHR (0.42) | TSHRMAOBTDP1ALDH1A1MAPK1 | |
| SCHEMBL3589545 | 1.00 | TSHR (0.42) | TSHRMAOBTDP1ALDH1A1MAPK1 | |
| SCHEMBL13995988 | 0.82 | MAOB (0.39) | TSHRMAOBALDH1A1MAPK1 | |
| SCHEMBL26138018 | 0.79 | TSHR (0.38) | TSHRMAOBTDP1 | |
| SCHEMBL824974 | 0.78 | — | — | |
| SCHEMBL29163758 | 0.76 | TSHR (0.40) | TSHRTDP1ALDH1A1 | |
| SCHEMBL26138022 | 0.75 | MAPT (0.36) | TSHRMAOB | |
| SCHEMBL19397686 | 0.74 | MAOB (0.35) | TSHRMAOBALDH1A1MAPK1 | |
| SCHEMBL14175019 | 0.74 | MAOB (0.35) | TSHRMAOBALDH1A1MAPK1 | |
| SCHEMBL19397681 | 0.74 | MAOB (0.35) | TSHRMAOBALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20100056575-A1 | Anesthetic Compounds | SIGNATURE THERAPEUTICS, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056575-A1 | Anesthetic Compounds | SIGNATURE THERAPEUTICS, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056575-A1 | Anesthetic Compounds | SIGNATURE THERAPEUTICS, INC. | 2010-03-04 | — | — | US | disclosed |
| WO-2008011539-A2 | ANESTHETIC COMPOUNDS | PHARMACOFORE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | TSHR 238/4885MAOB 1333/4885TDP1 4822/4885 |
| US-20100056575-A1 | Anesthetic Compounds | OPRL1, OPRM1, CYP3A5 | TSHR 3642/4885MAOB 595/4885TDP1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.